scholarly journals A Nationwide Survey of UK Oncologists’ Views on the Choice of Radiotherapy Regime for the Reconstructed Chest Wall in Breast Cancer Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Nicola Davis ◽  
Rema Jyothirmayi

Aims. This paper describes a UK survey of the choice of radiotherapy regime for the reconstructed chest wall in breast cancer patients. Questions focused on which fractionation regime consultants choose, their reasons for this, whether the type of reconstruction influences their choice, and whether bolus is used in patients who have undergone immediate reconstructive surgery. Materials and Methods. Between July 2014 and July 2015 a survey was sent by email to UK consultant radiation oncologists treating breast cancer. Results. The response rate was 73%. 67% of respondents use 40 Gray (Gy) in 15 fractions, with 22% using 50 Gy in 25 fractions and 7% using other regimes. For 90% of consultants the type of reconstruction did not influence their decision regarding choice of fractionation. 83% of respondents do not usually use a bolus for chest wall radiotherapy in patients who have had immediate reconstructive surgery. Conclusions. This survey illustrates there is variation in practice in the management of patients with breast cancer who have undergone immediate reconstructive surgery in the UK. There is a need for further research to determine which fractionation regime is optimal, whether the type of surgery is relevant, and whether bolus should be added.

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Manuela Fantini ◽  
Lorenzo Gianni ◽  
Carlotta Santelmo ◽  
Fabrizio Drudi ◽  
Cinzia Castellani ◽  
...  

The introduction of cisplatin in cancer treatment represents an important achievement in the oncologic field. Many types of cancers are now treated with this drug, and in testicular cancer patients major results are reached. Since 1965, other compounds were disovered and among them carboplatin and oxaliplatin are the main Cisplatin analogues showing similar clinical efficacy with a safer toxicity profile. Lipoplatin is a new liposomal cisplatin formulation which seems to have these characteristics. Lipoplatin was shown to be effective in NSCLC both in phase 2 and phase 3 trials, with the same response rate of Cisplatin, a comparable overall survival but less toxicity. A new protocol aiming to elucidate the double capacity of Lipoplatin to act as a chemotherapeutic and angiogenetic agent in triple-negative breast cancer patients is upcoming.


2011 ◽  
Vol 52 (3) ◽  
pp. 241-246 ◽  
Author(s):  
Takeshi Nagashima ◽  
Masahiro Sakakibara ◽  
Masami Kadowaki ◽  
Tiberiu Hiroshi Suzuki ◽  
Jissei Yokomizo ◽  
...  

Author(s):  
Geraldine M. Jacobson ◽  
Lee K. McNeely ◽  
Dennis D. Leavitt ◽  
J. Robert Stewart

2020 ◽  
Vol 301 (2) ◽  
pp. 565-571 ◽  
Author(s):  
Tanja Ignatov ◽  
Oliver Treeck ◽  
Thomas Kalinski ◽  
Olaf Ortmann ◽  
Atanas Ignatov

Sign in / Sign up

Export Citation Format

Share Document